Anti-Diabetes Drugs - Tanzania | Statista Market Forecast

The Anti-Diabetes Drugs market in Tanzania is expected to experience significant growth in the coming years.
By 2024, the projected revenue is estimated to reach US$46.07m Tanzanian Shillings.
This positive trend is anticipated to continue with an annual growth rate of 8.13% between 2024 and 2029, resulting in a market volume of US$68.11m Tanzanian Shillings by 2029.
In a global comparison, it is worth noting that United States is expected to generate the highest revenue in the Anti-Diabetes Drugs market, reaching a staggering US$37.84bn Tanzanian Shillings by 2024.
Tanzania's market for anti-diabetes drugs is witnessing a surge in demand due to the rising prevalence of diabetes in the country.

Definition:
The Anti-Diabetes Drugs market covers drugs to treat the metabolism disorder diabetes mellitus. It includes insulin and non-insulinotropic drugs such as glucagen-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. While patients with type 1 diabetes require lifelong insulin therapy, type 2 diabetes can also be treated with medication.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novo Nordisk, Eli Lilly, Sanofi, Merck & Co

Drugs to treat diabetes mellitus (oral intake and injections)
Insulin
Non-insulinotropic anti-diabetic drugs

Drugs to treat other metabolic disorders or other autoimmune diseases
Lipid-lowering agents
Drugs to treat hypertension
Diagnostics
Devices such as continuous glucose monitors

The Anti-Diabetes Drugs market in Tanzania has been experiencing steady growth in recent years.

Customer preferences: Tanzanian customers tend to prefer traditional medicines for treating diabetes, which has limited the growth of the Anti-Diabetes Drugs market in the country. However, there has been a growing awareness of the benefits of modern medicines, which has led to an increase in demand for Anti-Diabetes Drugs.

Trends in the market: The Anti-Diabetes Drugs market in Tanzania has been growing steadily due to an increase in the prevalence of diabetes in the country. The rise in the aging population and changing lifestyles have contributed to the increase in diabetes cases. Additionally, there has been an increase in the availability of Anti-Diabetes Drugs in the market, which has led to an increase in demand.

Local special circumstances: Tanzania's healthcare system is still developing, and there is a shortage of healthcare professionals in the country. This has limited the availability of Anti-Diabetes Drugs in some areas, and there is a need for more investment in the healthcare system to improve access to healthcare services.

Underlying macroeconomic factors: Tanzania's economy has been growing steadily in recent years, which has led to an increase in disposable income and an increase in the demand for healthcare services. The government has also been investing in the healthcare sector, which has led to an increase in the availability of Anti-Diabetes Drugs in the market. However, there are still challenges in the healthcare sector that need to be addressed to ensure sustainable growth in the Anti-Diabetes Drugs market.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

In 2021, diabetes mellitus caused an estimated 1.62 million deaths worldwide, making it the eighth leading cause of death. Furthermore, it is estimated that 537 million people are currently living with diabetes around the world, with this number projected to rise to some 783 million by the year 2045. Diabetes describes a group of metabolic diseases which cause high blood sugar levels. There are three types of diabetes: type 1 diabetes, type 2 diabetes, and gestational diabetes. However, the majority of diabetes cases are type 2, with an estimated 90 to 95 percent of diabetes cases in the United States type 2. Risk factors for type 2 diabetes include being overweight, being physically inactive, being 45 and older, and having prediabetes.